对重组活化凝血因子VII在临床实践中用于治疗血友病抑制物患者快速出血和控制急性疼痛的分析。 - Suppr

Suppr

超能文献

Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors.

作者信息

Salaj P, Ovesna P, Penka M, Hedner U

机构信息

Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

出版信息

Haemophilia. 2012 Nov;18(6):e409-11. doi: 10.1111/j.1365-2516.2012.02920.x. Epub 2012 Aug 29.

DOI:10.1111/j.1365-2516.2012.02920.x

PMID:22928909

Abstract

摘要

相似文献

Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors.对重组活化凝血因子VII在临床实践中用于治疗血友病抑制物患者快速出血和控制急性疼痛的分析。

Haemophilia. 2012 Nov;18(6):e409-11. doi: 10.1111/j.1365-2516.2012.02920.x. Epub 2012 Aug 29.

Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.在西班牙，重组活化因子 VII 与血浆源性活化凝血酶原复合物浓缩物治疗重型血友病 A 伴抑制物患者轻至中度出血发作的成本效益比较。

Haemophilia. 2013 Nov;19(6):841-6. doi: 10.1111/hae.12199. Epub 2013 Jun 11.

Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor.重组活化凝血因子 VII 在治疗继发于凝血因子 V 抑制剂的出血中的辅助作用。

Blood Coagul Fibrinolysis. 2008 Jun;19(4):327-8. doi: 10.1097/MBC.0b013e3283001d49.

Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature.重组活化凝血因子 VII 用于接受骨科手术的血友病抑制物患者：文献综述

Haemophilia. 2008 Mar;14(2):233-41. doi: 10.1111/j.1365-2516.2007.01617.x. Epub 2007 Dec 12.

A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.重组凝血因子VIIa在获得性出血性疾病中的应用的批判性评估。

Br J Haematol. 2006 May;133(4):355-63. doi: 10.1111/j.1365-2141.2006.06023.x.

Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors.血友病 A 伴抑制物患者难治性出血的病例研究。

Haemophilia. 2013 May;19(3):e151-66. doi: 10.1111/hae.12095. Epub 2013 Feb 4.

[Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].[重组活化因子VII在出血治疗与预防中的应用，不仅限于血友病]

Ned Tijdschr Geneeskd. 2002 Dec 28;146(52):2534-7.

Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).按出血类型和部位评估重组活化因子 VII（rFVIIA）在伴抑制物先天性血友病患者中的剂量和疗效：血友病和血栓形成研究学会（HTRS）登记处（2004-2008 年）的经验。

Haemophilia. 2012 Nov;18(6):990-6. doi: 10.1111/j.1365-2516.2012.02864.x. Epub 2012 May 28.

Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).重组活化因子 VII 在治疗伴有抑制物的先天性血友病患者的颅脑出血中的安全性和有效性：血友病和血栓形成研究学会登记处（2004-2008 年）的分析。

Haemophilia. 2010 Jul 1;16(4):625-31. doi: 10.1111/j.1365-2516.2010.02208.x. Epub 2010 Feb 10.

Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.WIRK 前瞻性、非干预性观察研究结果：重组活化因子 VII(rFVIIa)治疗伴有抑制剂的先天性血友病和其他出血性疾病患者。

Haemophilia. 2013 Sep;19(5):679-85. doi: 10.1111/hae.12156. Epub 2013 May 7.

引用本文的文献

Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).Aryoseven（重组活化凝血因子VII）在出血性疾病患者中的安全性评估（一项上市后观察性监测研究）

Iran J Pathol. 2016 Summer;11(3):204-209.

Pain and pain management in haemophilia.血友病中的疼痛与疼痛管理

Blood Coagul Fibrinolysis. 2016 Dec;27(8):845-854. doi: 10.1097/MBC.0000000000000571.

The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial.血友病抑制物患者报告的症状与关节出血时额外使用止血药物之间的潜在相关性：来自ADEPT2试验的重组活化因子VII数据的事后探索性分析。

Blood Coagul Fibrinolysis. 2017 Apr;28(3):224-229. doi: 10.1097/MBC.0000000000000584.

Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors: experience from developing countries.重组活化凝血因子 VII 用于 A 型或 B 型血友病及抑制剂患者关节积血的家庭治疗：发展中国家的经验

Blood Coagul Fibrinolysis. 2017 Mar;28(2):145-151. doi: 10.1097/MBC.0000000000000564.

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.重组因子 VIIa 类似物治疗伴抑制剂的血友病：vatreptacog alfa 的多中心、随机、对照试验结果。

J Thromb Haemost. 2014 Aug;12(8):1244-53. doi: 10.1111/jth.12634. Epub 2014 Jul 16.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验